FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3208147907> ?p ?o ?g. }

• W3208147907 endingPage "S56" @default.
• W3208147907 startingPage "S55" @default.
• W3208147907 abstract "Purpose/Objective(s)Locoregional control remains an issue in women with multi-node positive estrogen receptor-positive (ER+) breast cancer and many women with triple-negative breast cancer (TNBC). There is growing evidence that CDK4/6 inhibition (CDK4/6i) sensitizes breast cancer cells to ionizing radiation (RT) by suppressing the DNA damage response, but the role of RB is currently unclear. We sought to understand the role of RB and the implications of RB loss in ER+ and TNBC.Materials/MethodsClonogenic survival assays were used to calculate radiosensitivity and calculate enhancement ratios (rER). Cellular viability was quantified 72 hours after drug addition to calculate half-maximal inhibitory concentrations (IC50s). Phospho- and total RB expression levels were assessed by immunoblotting. DNA repair was assessed with γH2AX and RAD51 immunofluorescence. GFP-based plasmid reporter systems were used to assess homologous recombination (HR) and non-homologous end joining (NHEJ) competency. Isogenic RB1 knockout cells were generated with CRISPR-Cas9, and siRNA was used for transient RB1 knockdown. G1 cell cycle arrest was quantified using propidium iodide-based flow cytometry. In vivo efficacy of CDK4/6 inhibition + RT was assessed using MDA-MB-231 xenografts.ResultsFour TNBC cell lines with intact RB expression were radiosensitized (rER 1.08 – 2.22) after CDK4/6i with palbociclib, ribociclib, or abemaciclib, but two RB null TNBC models were not radiosensitized with combination treatment (rER: 0.84 – 1.00). In ER+ and TNBC cell lines, response to CDK4/6i + RT was accurately predicted by the presence or absence of RB protein, and higher RB expression led to increased radiosensitization of breast cancer cell lines at lower doses. In addition, pRB expression decreased in wild type TNBC cell lines treated with CDK4/6i + RT. HR was suppressed with CDK4/6i in RB wild type – but not mutant – cell lines. NHEJ efficiency in RB wild type TNBC was unchanged with CDK4/6i. Genetic knockdown of RB1 led to the loss of radiosensitization in ER+ and TNBC cell lines (rER: 0.84 – 1.13) as well as a decrease in sensitivity to CDK4/6i monotherapy. Parental and Cas9 control TNBC cells arrested in G1 24 hours after CDK4/6i and remained arrested at 48 hours, but RB1 CRISPR TNBC cells did not arrest after drug treatment. In a TNBC xenograft model with wild type RB expression (MDA-MB-231), CDK4/6i + RT led to significant radiosensitization in vivo and delayed time to tumor doubling.ConclusionRB loss mitigates CDK4/6 inhibitor-mediated radiosensitization of both ER+ and TNBC cells. Loss of RB expression prevents CDK4/6i-mediated radiosensitization, suggesting that RB expression may be a valuable clinical biomarker to predict efficacy of CDK4/6i + RT in future clinical trials. Our data also provide the preclinical rationale for CDK4/6i with RT not just in ER+ BC, but also in women with TNBC that express RB. Locoregional control remains an issue in women with multi-node positive estrogen receptor-positive (ER+) breast cancer and many women with triple-negative breast cancer (TNBC). There is growing evidence that CDK4/6 inhibition (CDK4/6i) sensitizes breast cancer cells to ionizing radiation (RT) by suppressing the DNA damage response, but the role of RB is currently unclear. We sought to understand the role of RB and the implications of RB loss in ER+ and TNBC. Clonogenic survival assays were used to calculate radiosensitivity and calculate enhancement ratios (rER). Cellular viability was quantified 72 hours after drug addition to calculate half-maximal inhibitory concentrations (IC50s). Phospho- and total RB expression levels were assessed by immunoblotting. DNA repair was assessed with γH2AX and RAD51 immunofluorescence. GFP-based plasmid reporter systems were used to assess homologous recombination (HR) and non-homologous end joining (NHEJ) competency. Isogenic RB1 knockout cells were generated with CRISPR-Cas9, and siRNA was used for transient RB1 knockdown. G1 cell cycle arrest was quantified using propidium iodide-based flow cytometry. In vivo efficacy of CDK4/6 inhibition + RT was assessed using MDA-MB-231 xenografts. Four TNBC cell lines with intact RB expression were radiosensitized (rER 1.08 – 2.22) after CDK4/6i with palbociclib, ribociclib, or abemaciclib, but two RB null TNBC models were not radiosensitized with combination treatment (rER: 0.84 – 1.00). In ER+ and TNBC cell lines, response to CDK4/6i + RT was accurately predicted by the presence or absence of RB protein, and higher RB expression led to increased radiosensitization of breast cancer cell lines at lower doses. In addition, pRB expression decreased in wild type TNBC cell lines treated with CDK4/6i + RT. HR was suppressed with CDK4/6i in RB wild type – but not mutant – cell lines. NHEJ efficiency in RB wild type TNBC was unchanged with CDK4/6i. Genetic knockdown of RB1 led to the loss of radiosensitization in ER+ and TNBC cell lines (rER: 0.84 – 1.13) as well as a decrease in sensitivity to CDK4/6i monotherapy. Parental and Cas9 control TNBC cells arrested in G1 24 hours after CDK4/6i and remained arrested at 48 hours, but RB1 CRISPR TNBC cells did not arrest after drug treatment. In a TNBC xenograft model with wild type RB expression (MDA-MB-231), CDK4/6i + RT led to significant radiosensitization in vivo and delayed time to tumor doubling. RB loss mitigates CDK4/6 inhibitor-mediated radiosensitization of both ER+ and TNBC cells. Loss of RB expression prevents CDK4/6i-mediated radiosensitization, suggesting that RB expression may be a valuable clinical biomarker to predict efficacy of CDK4/6i + RT in future clinical trials. Our data also provide the preclinical rationale for CDK4/6i with RT not just in ER+ BC, but also in women with TNBC that express RB." @default.
• W3208147907 created "2021-11-08" @default.
• W3208147907 creator A5005010217 @default.
• W3208147907 creator A5005345083 @default.
• W3208147907 creator A5014425420 @default.
• W3208147907 creator A5015285702 @default.
• W3208147907 creator A5036540537 @default.
• W3208147907 creator A5047365376 @default.
• W3208147907 creator A5057122527 @default.
• W3208147907 creator A5069748055 @default.
• W3208147907 creator A5070842981 @default.
• W3208147907 creator A5070894504 @default.
• W3208147907 creator A5073567939 @default.
• W3208147907 creator A5083302662 @default.
• W3208147907 date "2021-11-01" @default.
• W3208147907 modified "2023-09-27" @default.
• W3208147907 title "CDK4/6 Inhibition and Radiation as a Treatment Strategy to Improve Local Disease Control in Breast Cancers With Poor Prognoses" @default.
• W3208147907 doi "https://doi.org/10.1016/j.ijrobp.2021.07.143" @default.
• W3208147907 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34700581" @default.
• W3208147907 hasPublicationYear "2021" @default.
• W3208147907 type Work @default.
• W3208147907 sameAs 3208147907 @default.
• W3208147907 citedByCount "0" @default.
• W3208147907 crossrefType "journal-article" @default.
• W3208147907 hasAuthorship W3208147907A5005010217 @default.
• W3208147907 hasAuthorship W3208147907A5005345083 @default.
• W3208147907 hasAuthorship W3208147907A5014425420 @default.
• W3208147907 hasAuthorship W3208147907A5015285702 @default.
• W3208147907 hasAuthorship W3208147907A5036540537 @default.
• W3208147907 hasAuthorship W3208147907A5047365376 @default.
• W3208147907 hasAuthorship W3208147907A5057122527 @default.
• W3208147907 hasAuthorship W3208147907A5069748055 @default.
• W3208147907 hasAuthorship W3208147907A5070842981 @default.
• W3208147907 hasAuthorship W3208147907A5070894504 @default.
• W3208147907 hasAuthorship W3208147907A5073567939 @default.
• W3208147907 hasAuthorship W3208147907A5083302662 @default.
• W3208147907 hasBestOaLocation W32081479071 @default.
• W3208147907 hasConcept C121608353 @default.
• W3208147907 hasConcept C126322002 @default.
• W3208147907 hasConcept C143998085 @default.
• W3208147907 hasConcept C190283241 @default.
• W3208147907 hasConcept C203014093 @default.
• W3208147907 hasConcept C206684579 @default.
• W3208147907 hasConcept C2775930923 @default.
• W3208147907 hasConcept C2775934118 @default.
• W3208147907 hasConcept C2779744173 @default.
• W3208147907 hasConcept C2780110267 @default.
• W3208147907 hasConcept C29537977 @default.
• W3208147907 hasConcept C31573885 @default.
• W3208147907 hasConcept C502942594 @default.
• W3208147907 hasConcept C509974204 @default.
• W3208147907 hasConcept C530470458 @default.
• W3208147907 hasConcept C54355233 @default.
• W3208147907 hasConcept C553184892 @default.
• W3208147907 hasConcept C58962609 @default.
• W3208147907 hasConcept C71924100 @default.
• W3208147907 hasConcept C86803240 @default.
• W3208147907 hasConceptScore W3208147907C121608353 @default.
• W3208147907 hasConceptScore W3208147907C126322002 @default.
• W3208147907 hasConceptScore W3208147907C143998085 @default.
• W3208147907 hasConceptScore W3208147907C190283241 @default.
• W3208147907 hasConceptScore W3208147907C203014093 @default.
• W3208147907 hasConceptScore W3208147907C206684579 @default.
• W3208147907 hasConceptScore W3208147907C2775930923 @default.
• W3208147907 hasConceptScore W3208147907C2775934118 @default.
• W3208147907 hasConceptScore W3208147907C2779744173 @default.
• W3208147907 hasConceptScore W3208147907C2780110267 @default.
• W3208147907 hasConceptScore W3208147907C29537977 @default.
• W3208147907 hasConceptScore W3208147907C31573885 @default.
• W3208147907 hasConceptScore W3208147907C502942594 @default.
• W3208147907 hasConceptScore W3208147907C509974204 @default.
• W3208147907 hasConceptScore W3208147907C530470458 @default.
• W3208147907 hasConceptScore W3208147907C54355233 @default.
• W3208147907 hasConceptScore W3208147907C553184892 @default.
• W3208147907 hasConceptScore W3208147907C58962609 @default.
• W3208147907 hasConceptScore W3208147907C71924100 @default.
• W3208147907 hasConceptScore W3208147907C86803240 @default.
• W3208147907 hasIssue "3" @default.
• W3208147907 hasLocation W32081479071 @default.
• W3208147907 hasLocation W32081479072 @default.
• W3208147907 hasOpenAccess W3208147907 @default.
• W3208147907 hasPrimaryLocation W32081479071 @default.
• W3208147907 hasRelatedWork W1994659768 @default.
• W3208147907 hasRelatedWork W2071579635 @default.
• W3208147907 hasRelatedWork W2165101690 @default.
• W3208147907 hasRelatedWork W2356770811 @default.
• W3208147907 hasRelatedWork W2369254458 @default.
• W3208147907 hasRelatedWork W2393430761 @default.
• W3208147907 hasRelatedWork W2516370945 @default.
• W3208147907 hasRelatedWork W2918142254 @default.
• W3208147907 hasRelatedWork W3030232161 @default.
• W3208147907 hasRelatedWork W3031804774 @default.
• W3208147907 hasVolume "111" @default.
• W3208147907 isParatext "false" @default.
• W3208147907 isRetracted "false" @default.
• W3208147907 magId "3208147907" @default.
• W3208147907 workType "article" @default.